Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Beware of fake cancer drugs that have found their way into the booming online business of counterfeit prescription ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

And, in fact, this study showed that the additional palbociclib to this kind of treatment was able to significantly prolong ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a large clinical trial. Estimated ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

The development, pharmacology, safety, efficacy, and dosage and administration of trastuzumab are reviewed. The discovery of HER2 gene amplification in up to 30% of women with breast cancer led to ...

received an FDA complete response letter (CRL) on Jan. 3 for its TX-05 BLA, a biosimilar that references Roche AG’s Herceptin (trastuzumab). The CRL cites unnamed issues that need to be addressed by ...